Hence, the American Society of Clinical Oncology, European Society for Medical Oncology, and National Comprehensive Cancer Network adopted EGFR-TKI and ALK-TKI as first-line therapies for EGFR- and ALK-positive advanced NSCLC, respectively [12–14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.